Payment overview · 2025
General Payments
$159.51
8 reported records · 6 companies
Healthcare provider profile · identity verified
Cory Andrew Mcmahon, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · FORDYCE, AR · NPI 1679176002
Verified facts
What the public records show
CMS Open Payments records show Cory Andrew Mcmahon, APRN received $159.51 in general payments during 2025 across 8 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 41.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $65.39 | 41.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.82 | 18.1% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.25 | 10.8% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $16.97 | 10.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.06 | 10.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.02 | 9.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $159.51 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $65.39 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.82 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 373 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 275 | 60 |
| Potassium Chloride | Potassium Chloride | 262 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 257 | 73 |
| Furosemide | Furosemide | 247 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 245 | 65 |
| Gabapentin | Gabapentin | 237 | 46 |
| Losartan Potassium | Losartan Potassium | 206 | 46 |
| Tramadol Hcl | Tramadol Hcl | 202 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 177 | 36 |
| Metformin Hcl | Metformin Hcl | 170 | 44 |
| Meloxicam | Meloxicam | 161 | 41 |
| Simvastatin | Simvastatin | 160 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 36 |
| Omeprazole | Omeprazole | 146 | 34 |
| Trazodone Hcl | Trazodone Hcl | 146 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 72 |
| Donepezil Hcl | Donepezil Hcl | 129 | 25 |
| Jardiance | Empagliflozin | 124 | 21 |
| Lorazepam | Lorazepam | 122 | 27 |
| Lisinopril | Lisinopril | 121 | 30 |
| Mirtazapine | Mirtazapine | 121 | 26 |
| Buspirone Hcl | Buspirone Hcl | 104 | 22 |
| Celecoxib | Celecoxib | 104 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 104 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 13 |
| Allopurinol | Allopurinol | 98 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 98 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 98 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 89 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 89 | 27 |
| Clonazepam | Clonazepam | 87 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 83 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 83 | 21 |
| Amoxicillin | Amoxicillin | 81 | 65 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 22 |
| Pregabalin | Pregabalin | 81 | 17 |
| Azithromycin | Azithromycin | 79 | 65 |
| Glipizide | Glipizide | 79 | 18 |
| Ondansetron Odt | Ondansetron | 79 | 26 |
| Famotidine | Famotidine | 70 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | 11 |
| Sucralfate | Sucralfate | 64 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 62 | 41 |
| Eliquis | Apixaban | 61 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 57 | suppressed |
| Alprazolam | Alprazolam | 54 | 12 |
| Carvedilol | Carvedilol | 54 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | suppressed |
| Prednisone | Prednisone | 51 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 15 |
| Methocarbamol | Methocarbamol | 50 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 15 |
| Sertraline Hcl | Sertraline Hcl | 50 | 17 |
| Baclofen | Baclofen | 49 | suppressed |
| Glimepiride | Glimepiride | 49 | suppressed |
| Nifedipine Er | Nifedipine | 49 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 11 |
| Bupropion Xl | Bupropion Hcl | 48 | 11 |
| Ozempic | Semaglutide | 48 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 48 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 35 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 12 |
| Methylprednisolone | Methylprednisolone | 41 | 36 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 31 |
| Fluconazole | Fluconazole | 39 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 11 |
| Ibuprofen | Ibuprofen | 39 | 18 |
| Montelukast Sodium | Montelukast Sodium | 39 | suppressed |
| Levofloxacin | Levofloxacin | 38 | 22 |
| Meclizine Hcl | Meclizine Hcl | 37 | 17 |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 15 |
| Cefuroxime | Cefuroxime Axetil | 33 | 28 |
| Linzess | Linaclotide | 33 | suppressed |
| Methotrexate | Methotrexate Sodium | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | 13 |
| Diazepam | Diazepam | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Cefdinir | Cefdinir | 21 | 21 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Carisoprodol | Carisoprodol | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Constulose | Lactulose | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $159.51 · 8 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, CAPLYTA, ELIQUIS, INGREZZA, NURTEC ODT, Qelbree, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error